| TUFTS MEDICAL CENTER Patent applications |
| Patent application number | Title | Published |
|---|
| 20110184283 | SYSTEM AND METHOD OF CLINICAL TREATMENT PLANNING OF COMPLEX, MONTE CARLO-BASED BRACHYTHERAPY DOSE DISTRIBUTIONS - A system, method, and computer program product of clinical treatment planning implements complex Monte Carlo (MC) based brachytherapy dose distributions using conventional brachytherapy treatment planning systems (TPS). Dose distributions from complex brachytherapy source configurations determined with MC methods are used as inputs. Radial dose functions and 2D anisotropy functions are obtained by positioning the coordinate system origin along the dose distribution cylindrical axis of symmetry. Origin to tissue distance and active length are chosen to minimize TPS interpolation errors. A 2D anisotropy function is determined, and a brachytherapy dose rate constant is selected. A virtual brachytherapy source dose distribution is calculated based upon the complex treatment configuration. Additional dosimetry parameters may be considered as well, and dose distributions may be calculated and compared to the original MC-derived dose distributions. The present techniques may calculate dose to a specific tissue type instead of dose to water as used in the TG-43 formalism | 07-28-2011 |
| 20110184251 | BONE MINERAL DENSITY RATIOS AS A PREDICTOR OF OSTEOARTHRITIS - The present invention relates to systems, compositions, and methods for using bone mineral density ratios as a predictor of osteoarthritis. In particular, the present invention relates to comparing ratios of bone mineral density involving bones that are periarticular to determine a risk assessment for features of osteoarthritis. | 07-28-2011 |
| 20100317570 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor - The present invention includes peptidomimetic compound compositions and methods of making and using peptidomimetic compounds to modulate the activity of a peptide receptor for the treatment of one or more of hyperglycemia, insulin resistance, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia or other symptoms that relate to the function of the targeted receptor. The peptidomimetic includes an oligo-benzamide compound having at least three optionally substituted benzamides. | 12-16-2010 |
| 20100137207 | G PROTEIN COUPLED RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING G PROTEIN COUPLED RECEPTORS USING THE SAME - The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same. | 06-03-2010 |
| 20090317381 | CLEARANCE OF ABNORMAL IGA1 IN IGA1 DEPOSITION DISEASES - The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof. | 12-24-2009 |
| 20090130084 | Tagged IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 05-21-2009 |
| 20090041746 | Combination therapy with IgA1 proteases - The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, therapeutic agents for the treatment of diseases characterized by IgA deposition are provided. In particular, therapeutic agents to treat IgA nephropathy, Dermatitis herpetiformis (DH), and Henoch-Schoenlein purpura (HS) are disclosed. | 02-12-2009 |
